BMND07
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BMND07, or BMND-07, is a combination of either dimethyltryptamine (DMT) or 5-MeO-DMT and another undisclosed compound which is under development for the treatment of depressive disorders. It is being developed by Biomind Labs. As of March 2022, it is in phase 1 clinical trials.
BMND07, or BMND-07, is a combination of either dimethyltryptamine (DMT) or 5-MeO-DMT and another undisclosed compound which is under development for the treatment of depressive disorders. It is being developed by Biomind Labs. As of March 2022, it is in phase 1 clinical trials.
See also
List of investigational hallucinogens and entactogens List of investigational antidepressants
References
External links
Pipeline - Biomind Labs
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372016456 under CC BY-SA 4.0; modifications have been made.